14
Apr
2010
Posted in I - Series B, Q - 1Q10, R - WEST, X - Inflammation, X - Oncology, X - Pain, XX - CA
Tragara Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on selective biomarker for oncology, pain and inflammation therapeutics, closed a $5M Series B financing. Participants include Domain Associates, Mitsubishi Corp., Morgethaler Ventures, Oxford Bioscience Partners and ProQuest Investments.